Basit öğe kaydını göster

Cardiac effects of dapagliflozin in diabetic rats with subacute exposure

dc.contributor.authorBoran, Tuğçe
dc.contributor.authorÖzhan, Gül
dc.contributor.authorErcan, Feriha
dc.contributor.authorKaragöz Köroğlu, Ayça
dc.contributor.authorKaptan, Engin
dc.contributor.authorUlus Karaca, Bahar
dc.date.accessioned2022-07-04T15:34:17Z
dc.date.available2022-07-04T15:34:17Z
dc.date.issued2022
dc.identifier.citationBoran T., Ulus Karaca B., Karagöz Köroğlu A., Kaptan E., Ercan F., Özhan G., "Cardiac effects of dapagliflozin in diabetic rats with subacute exposure", ISTANBUL JOURNAL OF PHARMACY, cilt.52, sa.1, ss.8-13, 2022
dc.identifier.issn2587-2087
dc.identifier.otherav_b6ca52b5-7670-40d0-951a-51d9eea54c6a
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/184364
dc.identifier.urihttps://doi.org/10.26650/istanbuljpharm.2022.1038546
dc.description.abstractBackground and Aims: Dapagliflozin (DAPA) is a sodium-glucose co-transporter 2 (SGLT2) inhibitor used for the treatment of type 2 diabetes mellitus (T2DM) as a monotherapy or combination therapy with other antidiabetic medicines. The Food and Drug Administration (FDA) recently approved DAPA to minimize the risk of hospitalization due to heart failure in patients with T2DM because of its antihypertensive and antihyperglycemic activities. However, further study of DAPA is necessary to ensure the safety of patients.
dc.language.isoeng
dc.subjectPharmacology, Toxicology and Pharmaceutics (miscellaneous)
dc.subjectFarmakoloji ve Toksikoloji
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectSağlık Bilimleri
dc.subjectEczacılık
dc.subjectTemel Eczacılık Bilimleri
dc.subjectYaşam Bilimleri
dc.subjectTemel Bilimler
dc.subjectPharmacology
dc.subjectGeneral Pharmacology, Toxicology and Pharmaceutics
dc.subjectHealth Sciences
dc.subjectLife Sciences
dc.subjectDrug Guides
dc.subjectPharmacy
dc.subjectPharmacology (medical)
dc.subjectFARMAKOLOJİ VE ECZACILIK
dc.titleCardiac effects of dapagliflozin in diabetic rats with subacute exposure
dc.typeMakale
dc.relation.journalISTANBUL JOURNAL OF PHARMACY
dc.contributor.department, ,
dc.identifier.volume52
dc.identifier.issue1
dc.identifier.startpage8
dc.identifier.endpage13
dc.contributor.firstauthorID3417207


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster